+33.4%
MARA vs MRNA
+147.4%
-114.1%
-39.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | +0.7% | -4.9% | -4.1% |
| 7D | -1.5% | -8.2% | +6.8% | -1.1% |
| 30D | +18.1% | +125.6% | -107.5% | +6.1% |
| 3M | -9.4% | +197.1% | -206.5% | -29.2% |
| 6M | +33.4% | +148.5% | -115.1% | +13.7% |
| All | +33.4% | +147.4% | -114.1% | +13.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling